Genomic Precision

 A SeraCare blog focused on precision medicine and advanced clinical diagnostics

Customer Data: Use of Seraseq ctDNA Reference Samples to Validate Detection of Low Frequency Variants in a cfDNA-based NGS Lung Cancer Panel

Posted by Omo Clement, Ph.D. on Feb 14, 2019 2:10:00 PM

At the recently-concluded 2018 AMP Meeting, researchers at the New York Presbyterian Hospital (NYPH) and Weill Cornell Medical Center (WCMC) presented a poster1 on the validation of an Oncomine™ cell-free DNA Lung Assay using ctDNA NGS standards developed by SeraCare (Seraseq® ctDNA v2 Reference Materials),2

Read More

Topics: ctDNA, SeraSeq, cfDNA, #AMP2018, New York Presbyterian Hospital, Weill Cornell Medical Center

Keys to Better Liquid Biopsy Assay Sensitivity – AMP Corporate Workshop Video

Posted by Sam Blier on Jan 24, 2019 10:30:00 AM

“So as everyone here is aware, I’m sure, detection of circulating tumor DNA is challenging. There’s very little of it, to start with.” Hardly a revolutionary statement by Tony Godfrey, PhD, (Associate Chair, Surgical Research and Associate Professor of Surgery, Boston University School of Medicine) but an important acknowledgement from a leading expert of the difficulty faced by laboratorians

Read More

Topics: ctDNA, NGS reference materials, #AMP2018

Workshop Video: Two Experts Take on Clinical Genomics QC and Standardization at AMP

Posted by Sam Blier on Dec 18, 2018 4:45:00 PM

If you’ve attended the AMP Annual Meeting over the years or seen any of the headlines it generates, you know how next-generation sequencing-based assays are becoming indispensable diagnostic, prognostic, and predictive tools for a growing number of disease states. But just as important as the newest biomarker or latest chemistry – but seemingly less headline-worthy – are NGS quality control and standardization.

Read More

Topics: clinical genomics, iQ NGS, #AMP2018

Two Must-See Liquid Biopsy Poster Videos From AMP 2018

Posted by Sam Blier on Dec 7, 2018 2:19:00 PM

 

Of the many fantastic posters presented at AMP’s Annual Meeting in San Antonio, two concerning NGS-based liquid biopsy assays stood out. Both presenters described how their organizations are working to reliably detect pathogenic variants at extremely low allele frequencies – efforts critical to the clinical adoption of NGS-based liquid biopsy assays.

Read More

Topics: ctDNA, SeraSeq, cfDNA, #AMP2018

 
 
ebook CTA image square Jan2019

Subscribe for Updates

Recent Posts

Categories

see all